HKEx Stock Code: 01093English|繁體|简体
Home > Investor Relations > Announcements & Notices
Announcements & Notices
Nov
18
QUARTERLY RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2019
Nov
07
VOLUNTARY ANNOUNCEMENT - PRODUCT TRANSFER AGREEMENT
Nov
06
DATE OF BOARD MEETING
Nov
01
VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR THE GROUP'S "CEPHALEXIN CAPSULES"
Nov
01
VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR THE GROUP'S "CLINDAMYCIN HYDROCHLORIDE CAPSULES"
Nov
01
VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR THE GROUP'S "ENALAPRIL MALEATE TABLETS"
Oct
31
VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR THE GROUP'S "IBUPROFEN GRANULES"
Oct
31
VOLUNTARY ANNOUNCEMENT - "RECOMBINANT ANTI-EpCAM AND ANTI-CD3 HUMAN-MOUSE CHIMERIC BISPECIFIC ANTIBODY FOR INJECTION" WAS GRANTED CLINICAL TRIAL APPROVAL BY U.S. FDA
Oct
29
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE GROUP'S "DRONEDARONE HYDROCHLORIDE TABLET"
Oct
27
INSIDE INFORMATION - PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2019
Oct
22
VOLUNTARY ANNOUNCEMENT - ANTI-TUMOR NANODRUG "EPIRUBICIN HYDROCHLORIDE LIPOSOME INJECTION" WAS GRANTED CLINICAL TRIAL APPROVAL
Oct
21
VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG ALMB-0166 WAS GRANTED CLINICAL TRIAL APPROVAL IN AUSTRALIA
Oct
18
VOLUNTARY ANNOUNCEMENT - FIRST-IN-CLASS PRODUCT CANDIDATE ALMB-0168 GRANTED RARE PEDIATRIC DISEASE DESIGNATION BY THE U.S. FDA
Oct
14
INSIDE INFORMATION - ANNOUNCEMENT ON THE INDICATIVE RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2019 OF CSPC INNOVATION PHARMACEUTICAL CO., LTD.
Sep
26
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE GROUP'S "GLUTATHIONE FOR INJECTION"
Sep
26
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE GROUP'S "METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS"
Sep
23
FIRST-IN-CLASS PRODUCT CANDIDATE ALMB-0168 WAS GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA
Sep
10
VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR THE GROUP'S "CEFUROXIME AXETIL TABLETS"
Sep
02
VOLUNTARY ANNOUNCEMENT - RECOMBINANT ANTI-HER2 AND ANTI-CD3 HUMANIZED BISPECIFIC ANTIBODY FOR INJECTION WAS GRANTED CLINICAL TRIAL APPROVAL BY U.S. FDA
Aug
21
VOLUNTARY ANNOUNCEMENT - NEW TARGET ANTI-TUMOR DRUG "SYHA1801" WAS GRANTED CLINICAL TRIAL APPROVAL
Aug
19
VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSING AND COMMERCIALIZATION AGREEMENT
Aug
19
2019 INTERIM RESULTS ANNOUNCEMENT
Aug
18
INSIDE INFORMATION - PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD.* FOR THE HALF YEAR ENDED 30 JUNE 2019
Aug
15
VOLUNTARY ANNOUNCEMENT - SUBMISSION OF CLINICAL TRIAL APPLICATION FOR INVESTIGATIONAL FIRST-IN-CLASS NEW DRUG ALMB-0166 IN AUSTRALIA
Aug
07
DATE OF BOARD MEETING
Jul
29
VOLUNTARY ANNOUNCEMENT - NEW TARGET ANTI-TUMOR DRUG "SYHA1807" WAS GRANTED CLINICAL TRIAL APPROVAL
Jul
12
INSIDE INFORMATION - ANNOUNCEMENT ON THE INDICATIVE RESULTS FOR THE HALF YEAR ENDED 30 JUNE 2019 OF CSPC INNOVATION PHARMACEUTICAL CO., LTD.*
Jul
12
CONTINUING CONNECTED TRANSACTIONS - RENEWAL OF STEAM SUPPLY AGREEMENT
Jul
02
CHANGE OF ADDRESS OF SHARE REGISTRAR AND TRANSFER OFFICE
Jun
25
CONNECTED TRANSACTIONS - LEASE AGREEMENTS
Jun
13
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE GROUP'S "TICAGRELOR TABLETS"
Jun
10
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE GROUP'S "CLOPIDOGREL BISULFATE TABLETS"
May
27
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 27 MAY 2019
May
21
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
May
21
CHANGE OF VICE-CHAIRMAN AND ROTATING CHIEF EXECUTIVE OFFICER
May
21
QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2019
May
08
DATE OF BOARD MEETING
May
07
VOLUNTARY ANNOUNCEMENT - FORMATION OF JOINT VENTURE
Apr
28
INSIDE INFORMATION - PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD .* FOR THE THREE MONTHS ENDED 31 MARCH 2019
Apr
25
VOLUNTARY ANNOUNCEMENT - "PACLITAXEL CATIONIC LIPOSOME FOR INJECTION" FOR THE TREATMENT OF BREAST CANCER WAS GRANTED CLINICAL TRIAL APPROVAL
Apr
25
VOLUNTARY ANNOUNCEMENT - NEW ORAL ANTI-COAGULANT DRUG "SYHA136" WAS GRANTED CLINICAL TRIAL APPROVAL
Apr
17
NOTICE OF ANNUAL GENERAL MEETING
Apr
12
VOLUNTARY ANNOUNCEMENT - "SYHA1803" FOR THE TREATMENT OF INTRAHEPATIC CHOLANGIOCARCINOMA AND UROTHELIAL CARCINOMA WAS GRANTED CLINICAL TRIAL APPROVAL
Apr
12
VOLUNTARY ANNOUNCEMENT - "SYHA1402" FOR THE TREATMENT OF DIABETIC NEUROPATHY WAS GRANTED CLINICAL TRIAL APPROVAL
Mar
21
UPDATES ON THE SPIN-OFF AND SEPARATE LISTING OF CSPC XNW GROUP ON THE CHINEXT OF SHENZHEN STOCK EXCHANGE
Mar
18
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2018
Mar
06
DATE OF BOARD MEETING
Mar
05
VOLUNTARY ANNOUNCEMENT - SUBMISSION OF NDA TO U.S. FDA FOR LEVOAMLODIPINE MALEATE TABLETS
Mar
05
PROGRESS UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF CSPC XNW GROUP ON THE SHENZHEN STOCK EXCHANGE
Mar
03
PROGRESS UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF CSPC XNW GROUP ON THE SHENZHEN STOCK EXCHANGE
Feb
26
VOLUNTARY ANNOUNCEMENT - PRODUCT CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENTS
Jan
15
GRANT OF SHARES PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY
Jan
10
UNUSUAL PRICE AND TRADING VOLUME MOVEMENT
Jan
07
VOLUNTARY ANNOUNCEMENT - ACQUISITION OF 100% INTEREST IN YONG SHUN TECHNOLOGY DEVELOPMENT LIMITED
Jan
04
VOLUNTARY ANNOUNCEMENT - PRODUCT CO-DEVELOPMENT AND STRATEGIC COLLABORATION AGREEMENT

Please download the latest "Acrobat Reader" to view the PDF.

© Copyright 2019 CSPC Pharmaceutical Group Limited. All Rights Reserved.
Disclaimer